Ovarian Cancer Pipeline Summary

DelveInsight’s, “Ovarian Cancer - Pipeline Insight, 2026” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Ovarian Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Ovarian Cancer: Understanding

Ovarian Cancer: Overview

Ovarian cancer is a heterogeneous group of malignant tumors arising from the ovary and, in some classifications, closely related fallopian tube and peritoneal tissues. It is the second most common cancer of the female reproductive organs after endometrial cancer and occurs predominantly in postmenopausal women, with most cases diagnosed between 55 and 70 years of age. Ovarian cancer is characterized by diverse histological and molecular subtypes, with epithelial tumors accounting for approximately 90–95% of cases. Around 70% of patients are diagnosed at an advanced FIGO stage (III–IV), largely because early disease often produces nonspecific symptoms and there is no effective screening method for the general population.

The development of ovarian cancer is multifactorial and involves genetic, reproductive, hormonal, and other risk factors. One of the strongest established genetic risk factors is the presence of pathogenic mutations in BRCA1 and BRCA2, which account for a substantial proportion of hereditary ovarian cancers. Lynch syndrome is another important inherited risk factor. Reproductive factors also influence risk, with pregnancy, childbirth, breastfeeding, and hormonal contraception associated with reduced risk, potentially through suppression of ovulation and reduced repeated damage to the ovarian epithelium. Hormonal factors may also contribute to carcinogenesis, as ovarian cancer cells can express estrogen receptors, particularly ER?.

Ovarian cancer comprises biologically distinct tumor types. Epithelial ovarian cancers are broadly divided into type I and type II tumors. Type I tumors, including low-grade serous, endometrioid, clear cell, and mucinous carcinomas, generally develop more slowly and may harbor alterations in genes such as KRAS, BRAF, HER2, PIK3CA, and PTEN. Type II tumors, which include predominantly high-grade serous carcinomas, are more aggressive, grow rapidly, are frequently diagnosed at an advanced stage, and are commonly associated with TP53 and BRCA1/2 alterations. Estrogen signaling may also contribute to ovarian tumor development by influencing cancer-cell proliferation, invasion, apoptosis, cell-cycle regulation, and inflammation through estrogen receptors such as ER? and ER?.

Diagnosis of ovarian cancer involves clinical assessment, imaging, tumor-marker evaluation, and definitive histopathological confirmation. Initial evaluation may include a gynecological examination, abdominal and transvaginal ultrasound, and laboratory testing. CA-125 and HE4 can be assessed, with the ROMA (Risk of Ovarian Malignancy Algorithm) incorporating CA-125, HE4, and menopausal status to estimate the likelihood of ovarian malignancy. CT imaging of the abdomen and pelvis, along with chest imaging, may be used to evaluate the extent of disease. However, definitive diagnosis is established through histopathological examination of tumor tissue, which also helps determine the histological type and disease stage according to the FIGO classification.

Treatment is primarily based on the stage, histological and molecular characteristics of the tumor, and the patient's clinical condition. Cytoreductive surgery is a fundamental component of treatment and aims to achieve optimal removal of visible tumor. Surgery is generally combined with platinum-based chemotherapy and paclitaxel, with treatment decisions made according to disease stage and resectability. The review also describes targeted and hormonal approaches, including PARP inhibition with olaparib for maintenance therapy in selected patients with recurrent serous ovarian cancer, as well as hormonal therapies such as selective estrogen receptor modulators, aromatase inhibitors, and gonadotropin-releasing hormone agents. Radiotherapy has a more limited role and is used less frequently.

"Ovarian Cancer- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ovarian Cancer pipeline landscape is provided which includes the disease overview and Ovarian Cancer treatment guidelines. The assessment part of the report embraces, in depth Ovarian Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ovarian Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Ovarian Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Ovarian Cancer.

Ovarian Cancer Emerging Drugs Chapters

This segment of the Ovarian Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Ovarian Cancer Emerging Drugs

• Mocertatug rezetecan (GSK5733584): GSK/ Hansoh Pharma

Mocertatug rezetecan (GSK5733584) is an investigational B7-H4-targeted antibody-drug conjugate (ADC) being evaluated in ovarian cancer. It is composed of a fully human anti-B7-H4 monoclonal antibody covalently linked to a topoisomerase I inhibitor payload, with a drug-to-antibody ratio (DAR) of 6. B7-H4 is widely expressed in ovarian cancer and has limited expression in normal tissues, supporting its use as a tumor target. The drug is designed to bind to B7-H4 on tumor cells and deliver the cytotoxic topoisomerase inhibitor payload to the cancer cells, where inhibition of topoisomerase I is expected to contribute to antitumor activity. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Ovarian Cancer.

• Raludotatug deruxtecan: Merck/ Daiichi Sankyo

Raludotatug deruxtecan (MK-5909) is an investigational antibody-drug conjugate (ADC) consisting of a humanized anti-CDH6 IgG1 monoclonal antibody linked to a topoisomerase I inhibitor payload. It is being evaluated in ovarian cancer, including platinum-resistant ovarian cancer. The drug is designed to bind to CDH6, which is expressed on tumor cells, and deliver the cytotoxic payload to these cells. Following binding and internalization, the topoisomerase I inhibitor payload is released and inhibits topoisomerase I, leading to DNA damage and tumor-cell death. The drug is being developed in collaboration with Daiichi Sankyo. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Ovarian Cancer.

• JAB-30355: Jacobio Pharmaceuticals Co., Ltd.

JAB-30355 is an orally bioavailable small molecule activator for the treatment of patients with solid tumors harboring P53 Y220C mutation. JAB-30355 shows very high binding affinity to P53 Y220C mutant proteins and can maximally restore the proper folding and functionality of misfolded P53 Y220C upon binding, trigger apoptosis in vitro. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Ovarian Cancer.

• THEO-260: Theolytics Limited

THEO-260 is a next-generation oncolytic adenovirus being developed for ovarian cancer, including platinum-resistant ovarian cancer. It is an oncolytic immunotherapy designed to target and destroy both ovarian cancer cells and cancer-associated fibroblasts (CAFs) within the tumor microenvironment. THEO-260 uses a unique dual-targeting mechanism to directly lyse cancer cells and CAFs, while also inducing immunogenic cell death and T-cell activation, thereby helping to alleviate the immune-suppressive tumor microenvironment. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Ovarian Cancer.

• ABBV-901: AbbVie

ABBV-901 is an investigational antibody-drug conjugate (ADC) being developed for ovarian cancer. It is designed to target folate receptor alpha (FR?), a protein expressed on the surface of certain tumor cells, and selectively deliver its therapeutic payload to FR?-expressing cancer cells. By combining the targeting properties of a monoclonal antibody with the cytotoxic activity of its payload, ABBV-901 is intended to provide targeted antitumor activity while limiting exposure to non-target cells. ABBV-901 is currently being investigated in Phase I for ovarian cancer.

• ERNA-101: Ernexa Therapeutics

ERNA-101 is an investigational allogeneic induced mesenchymal stem cell (iMSC) therapy derived from induced pluripotent stem cells (iPSCs), being developed for platinum-resistant ovarian cancer. ERNA-101 is engineered to naturally home to tumor sites and secrete an IL-7/IL-15 fusion cytokine directly within the tumor microenvironment (TME). This localized delivery is designed to remodel the immunosuppressive tumor microenvironment into an immune-activated environment, while limiting systemic exposure. The IL-7/IL-15-mediated immune activation enhances the activity, infiltration, survival, and persistence of cancer-fighting CD4+ and CD8+ T cells, promoting a stronger immune response against tumor cells. Currently, the drug is being evaluated in the Preclinical stage of its development for the treatment of Ovarian Cancer.

Further product details are provided in the report……..

Ovarian Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Ovarian Cancer drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Ovarian Cancer

There are approx. 180+ key companies which are developing the therapies Ovarian Cancer. The companies which have their Ovarian Cancer drug candidates in the most advanced stage, i.e. Phase III include, GSK, and others.

• Phases

DelveInsight’s report covers around 200+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Ovarian Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Ovarian Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ovarian Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ovarian Cancer drugs.

Ovarian Cancer Report Insights

• Ovarian Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Ovarian Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Ovarian Cancer drugs?
• How many Ovarian Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ovarian Cancer?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ovarian Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Ovarian Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• GSK
• Merck
• Orion
• Daiichi Sankyo
• Sichuan Kelun-Biotech
• Astrazeneca
• Jacobio Pharmaceuticals Co., Ltd.
• Compugen Ltd
• AbbVie
• Outpace Bio
• Phrontline Biopharma
• OnCusp Therapeutics, Inc.
• Theolytics Limited
• Jiangsu Hengrui Pharmaceuticals
• Glenmark Pharmaceuticals
• Incyte Corporation
• Amplia Therapeutics
• Ernexa Therapeutics
• Temple Therapeutics
• Aurealis Therapeutics
• Nerviano Medical Sciences
• Xencor, Inc.

Key Products

• GSK5733584 (mocertatug rezetecan)
• ifinatamab deruxtecan (MK-2400)
• opevesostat
• raludotatug deruxtecan (MK-5909)
• sacituzumab tirumotecan
• AZD5335
• JAB-30355
• JAB-8263
• COM701
• ABBV-901
• Temab-A (ABBV-400)
• OPB-101
• TJ102
• CUSP06
• THEO-260
• Trastuzumab rezetecan (SHR-A1811)
• INCB123667
• Narmafotinib
• ERNA-101
• TTX335o
• AUP-55
• Itareparib (NMS-293)
• XmAb541